Transaction · 0000914190-26-000132
TECHBIO-TECHNE Corp
Hippel James
Hippel James, CFO, reported a transaction classified as grant at BIO-TECHNE Corp involving 22438.000000 shares for an estimated $0.00. Reported holdings after the transaction were 22438.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
grantSEC transaction code ACFO
- Trade date
- Aug 17, 2026
- Filing date
- Aug 19, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
TECH price since this filing
Daily closing prices, with the filing date and available return windowsTECH · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -0.5%1w ago -0.5%1d ago -0.1%
Returns since7d -0.1%30d -0.1%90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0000914190-26-000132 Restricted Stock Units
- Transaction date
- Aug 17, 2026 Filed Aug 19, 2026, 08:48 PM · 2d delay
- Shares
- 22,438 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 22,438 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
Mixed or weak signal
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
CFO
Officer YesDirector No10% NoOther No
Footnotes & amended
- F1
Fully exercisable.
- F2
Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
- F3
Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
- F4
Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
- F5
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
- F6
Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F7
Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F8
4,011 restricted stock units vest on 8/15/2027.
- F9
11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
- F10
4,903 restricted stock units vest on 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
- F11
7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029.
- F12
36,459 restricted stock units vest on 8/17/2029.
Related transactions
Same SEC filing0 other transactions
Recent company activity
TECH0 recent txs